Arquitos Capital Management Q3 2025 Investor Letter

Performance Overview - Arquitos achieved a net return of 29.6% in Q2 2025, with a year-to-date return of 66.8% [3] - The fund's performance is evaluated on an absolute basis rather than relative to market indices [4][5] - The S&P 500 has returned 14.4% annually since the fund's inception, while small caps, represented by the Russell 2000, have returned 10.0% annually [7] Benchmarking Strategy - The Russell 2000 Small Cap Index will be used as the primary benchmark for Arquitos, reflecting the focus on smaller companies [9] - The fund's strategy involves holding investments for extended periods, allowing for business evolution and market recognition [10] Key Holdings Liquidia Corporation (LQDA) - Liquidia's share price increased from $11.76 to $22.74 in 2025, primarily through long-dated call options [10] - The FDA approved Liquidia's product Yutrepia in May 2025, which has shown strong initial demand with over 900 prescriptions in the first 11 weeks [11][12] - The share price may be affected by the upcoming ruling in the '327 patent dispute, with expectations of a favorable outcome [14] ENDI Corp (OTCQB:ENDI) - ENDI's share price rose from $11.43 to $17.50, with assets under management increasing to $4.2 billion [18][19] - The company holds approximately $53 million in cash and investments, with a market capitalization of about $95 million [20] Finch Therapeutics (OTCPK:FNCH) - Finch's share price increased from $11.30 to $12.28, following a jury trial win against Ferring Pharmaceuticals [21][22] - The potential for enhanced damages from the trial verdict could significantly increase Finch's share value [23] Investment Philosophy - The investment strategy emphasizes patience and long-term value, with a focus on total return over the holding period [24][25] - The fund's performance has been strong in 2025, with expectations for continued undervaluation in core holdings [25]